Welcome to our dedicated page for Sunset Capital news (Ticker: SNST), a resource for investors and traders seeking the latest updates and insights on Sunset Capital stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sunset Capital's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sunset Capital's position in the market.
Aphex BioCleanse Systems (OTCPK: SNST) announced a significant purchase order from eTECH Channel for its non-toxic Hy-IQ® Water disinfecting wipes, marking a pivotal opportunity in the sanitation market. The initial order involves 4,950 gallons of DermAphex® product, aimed at fulfilling demands from major retail clients. Aphex's wipes are FDA-compliant for hand disinfecting, set to be available in retail and healthcare settings soon. eTECH Channel, experienced in PPE sales, is launching these U.S.-made, kid-safe products, indicating strong market interest and a potential expansion of distribution channels.
Aphex BioCleanse Systems (OTCPK: SNST) has expanded its product line to include non-toxic sanitizing wipes featuring its patented Hy-IQ® Water technology. The growing demand for sanitizing products, amplified by the COVID-19 pandemic, presents substantial market opportunities. Aphex's sanitizing wipes are uniquely water-based and non-toxic, aiming to capture a share of the projected $30.11 billion disinfectant market by 2027. Additionally, the company is poised to establish partnerships with key distributors to enhance market reach.
Aphex BioCleanse Systems, Inc. (OTCPK: SNST) announced the addition of Kevin Harrington and Mark Timm as advisors to enhance its growth in the sanitization market during the COVID-19 pandemic. With high demand for effective sanitization products, including Aphex's alcohol-free DermAphex®, the company is poised for significant growth. Harrington, a veteran entrepreneur, has a track record of generating over $5 billion in sales and launching numerous successful products. This strategic move aims to capitalize on the expected 46% CAGR in the hand sanitizer market in 2020.
Summary not available.
Aphex BioCleanse Systems, Inc. (OTC: SNST) has appointed CMW Media as its strategic communications partner to enhance the recognition of its innovative, chemical-free sanitization products. The partnership aims to educate the public about the safety issues related to alcohol-based sanitizers, as demand for hand sanitizers surged due to COVID-19. Aphex also announced a merger intention with Sunset Capital Assets, expanded its manufacturing facility, and initiated a clinical trial for its HydrAphex® hand sanitizer. The company is seeking FDA approval for its unique non-alcohol sanitizer technology.
Aphex BioCleanse Systems, Inc. (OTC: SNST) has appointed Hancock Askew & Co., LLP as its new PCAOB-qualified auditor and hired an accounting consultant to strengthen its internal accounting team. The decision aims to enhance compliance and financial reporting, with plans to file with the SEC later this year. Hancock Askew brings over 100 years of auditing experience and specializes in public company services. CEO David J. Weaver expressed confidence in the new partnership, while consultant Chuck Ragland aims to improve shareholder transparency and trust.
Aphex BioCleanse Systems (OTC: SNST) has announced a collaboration with Now Biopharma to conduct a clinical trial for its hand sanitizer, HydrAphex®. This trial will include 300 human subjects and will compare HydrAphex® with an approved alcohol-based product and a saline control. The product claims to inactivate a wide range of pathogens, including the SARS-CoV-2 virus. Aphex is seeking FDA approval for its non-toxic, non-alcohol formula, which utilizes Hy-IQ™ Water. This trial aims to gather data to support the product's safety and efficacy.